



# IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

13 April 2023

## Imagion Biosystems April 2023 Investor Newsletter

MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to provide its investors with its April 2023 Investor Newsletter.

The newsletter details recent new company developments and activities, including:

- Message from the CEO, Mr Robert Proulx;
- Update on Imagion's commercial partner outreach efforts;
- MRI driving new areas for IP and Analytics;
- Upcoming events (including participation at Ovarian Cancer conference); and
- Imagion Biosystems in the news.

The investor newsletter can be viewed below or at this link:

<https://imagionbiosystems.hubspotpagebuilder.com/just-in-the-april-2023-investor-newsletter>.

Imagion Biosystems normally distributes this update as an e-newsletter. Investors can sign up to receive email updates at this link: <https://info.imagionbio.com/newsletter-signup>

**-ENDS**

### About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible.

For further information please visit [www.imagionbiosystems.com](http://www.imagionbiosystems.com)

### Authorisation & Additional information

This announcement was authorised by the Disclosure Committee of Imagion Biosystems Limited

#### U.S. Media Contact:

Casie Ost

[Casie.ost@imagionbio.com](mailto:Casie.ost@imagionbio.com)

+1-619-693-4428

#### Australian Media & Investor Relations:

Hannah Howlett, WE Communications

[We-AUImagionBiosystems@we-worldwide.com](mailto:We-AUImagionBiosystems@we-worldwide.com)

+61 (0) 450648064



Investor Newsletter: Issue 17 | Apr 2023

## Newsletter Highlights:

1. Clinical data and expert review triggers commercial partner outreach efforts
2. MRI utility drives new IP and AI/ML efforts
3. Upcoming events and a recap on key media coverage


## A Message From the CEO

As we noted in our 2022 Annual Report, last year was a momentous year having reported results from the first cohort of subjects in the MagSense<sup>®</sup> HER2 Phase 1 study at a global breast cancer meeting and presenting our prostate cancer imaging agent at an imaging conference.

That momentum has continued in the first quarter of this year with the independent review we reported at the beginning of February and the recent news of our communications with the FDA related to our plans to file an IND and proceed with a multi-site study in the U.S. for the MagSense<sup>®</sup> HER2 imaging agent.

In this newsletter, we are pleased to share some of the additional activities we are undertaking to keep the momentum going.

We look forward to keeping all our stakeholders apprised of the work we are doing to change the way we look at cancer with our MagSense® molecular imaging technology.

  
Robert (Bob) Proulx  
Executive Director and CEO  
Imagion Biosystems, Ltd



---

## Strategic Partnering Data Room

Our MagSense® imaging agents could be the first-of-its-kind molecular imaging solution for MRI. By changing current practice in medical imaging to include the sensitive and selective detection of cancer cells without using radiation, Imagion's technology could significantly improve cancer diagnosis and patient care.

Now that our MagSense® imaging agent for HER2 breast cancer detection is progressing towards Phase 2 and our technology is showing positive preclinical results in other areas of high unmet need, including prostate cancer and ovarian cancer, we have a substantial value proposition for the medical imaging sector and are now well-placed to initiate discussions around strategic options with potential commercial partners. Our current pipeline represents a projected global market opportunity of ~ \$5Billion\* for Imagion and our partner(s).

To facilitate the process, we have established a secure data room where we can share confidential information related to the MagSense® HER2 program as well as our growing pipeline of imaging agents and will begin outreach programs to potential partners in an effort to gauge market interest in our technology.

Parties interested in partnering with Imagion to commercialize our MagSense® molecular imaging technology can contact us via [partnering@imagionbio.com](mailto:partnering@imagionbio.com).

\* Total available market estimates based on market data of current testing and a projected MagSense® price of \$1200.

---

## MRI Utility Drives New Areas for IP and Analytics

Data from the MagSense® HER2 Phase 1 study and internal R&D programs have opened new opportunities for Imagination to file for intellectual property and are driving efforts to investigate how analytical methods in Artificial Intelligence (AI) and Machine Learning (ML) might be applied to improve the clinical utility of the MagSense® imaging tests.

A provisional patent application has been filed related to the image pattern(s) associated with presence of the MagSense® targeted imaging agent. This new IP would extend our proprietary position for our magnetic nanoparticles across both magnetic relaxometry and magnetic resonance imaging, providing broader protection against other imaging agents that might try to replicate targeted detection by MRI. While there is no guarantee that the patent will issue, the new IP would provide significant value to Imagination and its commercial partners, carving out a unique space in the medical imaging landscape.

Additionally, the Company has initiated a project with a 3rd party with expertise in image analysis methods including AI and ML, to determine if algorithmic solutions could be applied to the MRI scans resulting from a MagSense® test to improve interpretability. Data from the Phase 1 study has informed the initial investigations and the Company is now looking into how algorithmic solutions may help drive improvements in image acquisition in the Phase 2 study. If algorithmic solutions can be applied, it would open the opportunity for the MagSense® imaging agents to be sold with an associated Software as a Medical Device (SaMD) solution to aid radiologists in the interpretation of the MagSense® test results.

Since all MagSense® targeted imaging agents use the same underlying magnetic nanoparticle technology, the Company would look to apply the intellectual property and image analysis solutions broadly across the portfolio of MagSense® nanoparticle imaging agents.

---

## **AACR 2023 Meeting - Multiple Posters Accepted**

We are pleased to confirm we have two scientific posters related to our ovarian cancer detection program that will be presented at the Annual Association of Cancer Research (AACR) meeting being held in Orlando, Florida April 14-19, 2023. Poster info below:

**Title:** Targeted Detection of Ovarian Cancer Using Functionalized Iron Oxide Nanoparticles

**Session:** Tues, April 18 9:00am - 12:30pm

**Poster:** Section 3, #15; Abstract 3590

**Title:** In Vivo Targeted Detection and Imaging of Ovarian Cancer by SPMR and MRI Using Anti-Folate Receptor Functionalized Iron Oxide Nanoparticles

**Session:** Tues, April 18 9:00am - 12:30pm

**Poster:** Section 3, #11; Abstract 3586

*Copies of the posters will be available following the close of the meeting.*

*You may request a copy once available.*

Request AACR Posters Here

---

## Other Recent News

### Society of Thermal Medicine Meeting

Imagion will be at the [Society of Thermal Medicine Meeting](#) in San Diego on April 27-29, where some of our PrecisionMRX® nanoparticle end users will be presenting papers, demonstrating the use of iron oxide nanoparticles in hyperthermia and related research.

Maintaining a presence at these specialty meetings is key to identifying future clinical and commercial opportunities as we work to establish Imagion as a leading biomedical nanoparticle company.

---

### Pitt Street Research Report

Pitt Street Research has recently published a 27-page overview report on Imagion Biosystems, Limited. This detailed report includes close examinations of the

company's business and investment potential.


[Read the Full Review ⇒](#)



## Dr. Boreham's Crucible Review

Tim Boreham reviewed Imagination in “Dr. Boreham’s Crucible” column on Biotech Daily, where he discusses the results of our independent review and Imagination’s plans moving forward, while taking a deep-dive into what our team is trying to achieve – a safe, non-invasive way of looking at cancer in the body.

[Read the Full Review ⇒](#)



## Discussing the Future of MagSense with 180Markets

In case you missed the 180Markets interview with Imagion's CEO, Bob Proulx, discussing the future of cancer detection and how our MagSense medical imaging technology plans to make a difference.

[Watch the full interview here ⇒](#)



---

## Entitlement Offer Info

We are currently conducting a pro-rata non-renounceable entitlement offer to existing eligible shareholders. For offer information, [please visit our website ⇒](#)

---

Questions? Reach the Investor Relations department by emailing [investor@imagionbio.com](mailto:investor@imagionbio.com)

**Be sure to connect with us on social:**



*Copyright © 2023 Imagion Biosystems, All rights reserved.*

You're receiving this email because you have requested information about Imagion Biosystems.

Imagion Biosystems, 5601 Oberlin Drive, Suite 100, San Diego, CA 92121-1722, United States

[Unsubscribe](#) [Manage preferences](#)